Spironolactone may reduce the risk of incident rosacea.
-
Spoendlin J
Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland; Hospital Pharmacy, University Hospital Basel, Basel, Switzerland.
-
Voegel JJ
Galderma Research and Development, Sophia Antipolis, France.
-
Jick SS
Boston Collaborative Drug Surveillance Program, Boston University, Lexington, Massachusetts, USA.
-
Meier CR
Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland; Hospital Pharmacy, University Hospital Basel, Basel, Switzerland; Boston Collaborative Drug Surveillance Program, Boston University, Lexington, Massachusetts, USA. Electronic address: christoph.meier@usb.ch.
Show more…
Published in:
- The Journal of investigative dermatology. - 2013
-
Language
-
-
Open access status
-
bronze
-
Identifiers
-
-
Persistent URL
-
https://sonar.ch/global/documents/90238
Statistics
Document views: 52
File downloads: